TerminatedPhase 2ACTRN12607000444482

A Double Blind, Placebo Controlled Parallel Group Study to Assess the Efficacy, Safety and Tolerability of CAT-354 in Subjects with Uncontrolled Asthma Despite Optimal Treatment

Sponsor

Cambridge Antibody Technologies

Enrollment

228 participants

Start Date

Sep 1, 2007

Study Type

Interventional

Conditions

Uncontrolled Asthma

Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 80 Yearss

Plain Language Summary

Simplified for easier understanding

This study tests a drug called CAT-354 for people whose asthma remains uncontrolled despite taking high-dose inhalers and other medications. It is open to adults aged 18 to 80 with uncontrolled asthma. Participants will receive injections of the study drug or placebo and have lung function and symptoms monitored.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

CAT-354 (Anti-IL-13 HuMab) recombinant human monoclonal antibody of the G4 subclass that neutralises interleukin-13 (IL-13). Each subject will receive intravenous infusions with CAT-354 or placebo

CAT-354 (Anti-IL-13 HuMab) recombinant human monoclonal antibody of the G4 subclass that neutralises interleukin-13 (IL-13). Each subject will receive intravenous infusions with CAT-354 or placebo. Dose will be adjusted to body weight. CAT-354 at the following doses: - 1 mg/kg CAT-354 on Day 0, 28, and 56; - 5 mg/kg CAT-354 on Day 0, 28, and 56; - 10 mg/kg CAT-354 on Day 0, 28, and 56. Patient participation will be a maximum of 112 days (including a 14 to 28 day screening period)